Abstract 31P
Background
The incidence of breast cancer among young women has been steadily increasing. Early detection and comprehensive treatment are crucial to enhance survival and improve the quality of life for these patients. The incidence of breast cancer among young women has been steadily increasing. Early detection and comprehensive treatment are crucial to enhance survival and improve the quality of life for these patients.
Methods
Young breast cancer patients treated at Basavatarakam Indo-American Cancer Hospital & Research Institute between January 2010 and December 2014 were followed. Their clinical characteristics, stage, treatment outcomes, and survival rates were analysed.
Results
During the study period, 508 young breast cancer patients were treated and subsequently followed up for 10 years. The median follow-up period was 51 months. The median age at diagnosis was 33.45 years (SD ± 4.39). Among all patients, 27.1% (n=138) were under 30 years old, and the majority (72.6%, n=369) were between 31 and 40 years old. Early breast cancer (EBC) was diagnosed in 67.1% (n=341) of patients, while 26.8% (n=136) had Locally Advanced Breast Cancer (LABC). De novo metastatic disease was found in 6.1% (n=31) of cases. Infiltrating ductal carcinoma was the most common subtype, seen in 97% (n=493) of cases. Hormone receptor positivity was found in 43.5% (n=211) of patients, and HER2neu testing was done in 30.5% (n=155) of cases, with 31% (n=48) testing positive. About 24.4% of patients (n=105) experienced relapse. Among these cases, 11.4% (n=12) involved locoregional recurrence, while 82.8% (n=87) had distant metastases. EBC had a 5-year disease-free survival (DFS) of 82.1% and overall survival (OS) of 88.7%. At 10 years, DFS was 76.9% and OS was 79.2%. LABC showed a 5-year DFS of 58.1% and OS of 79.5%. At 10 years, DFS was 56.1% and OS was 70.0%. Metastatic disease had a 5-year DFS of 22.8% and OS of 16.8%. At 10 years, DFS remained at 11.4% and OS was 16.8%.
Conclusions
Managing young breast cancer as a distinct entity is essential. The interplay of psychosocial factors and economics is crucial in shaping disease management and outcomes, particularly in settings with limited resources.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.